Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + SOX in Locally Advanced Gastric Cancer
NCT03192735Phase 2Unknown
- Start
- Sep 2017
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric cancer (GC). Primary endpoint: Radical surgical resection rate at 30 days. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03192735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192735.